"Capecitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.
| Descriptor ID |
D000069287
|
| MeSH Number(s) |
D03.383.742.680.245.500.425 D03.383.742.698.875.404.425 D13.570.230.329.313 D13.570.685.245.500.425
|
| Concept/Terms |
Capecitabine- Capecitabine
- N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
|
Below are MeSH descriptors whose meaning is more general than "Capecitabine".
Below are MeSH descriptors whose meaning is more specific than "Capecitabine".
This graph shows the total number of publications written about "Capecitabine" by people in this website by year, and whether "Capecitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Capecitabine" by people in Profiles.
-
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 Mar 27; 15(1):2691.
-
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
-
DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 05 20; 41(15):2701-2705.
-
Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.
-
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022 08 10; 40(23):2546-2556.
-
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.
-
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMBÂ trial). Eur J Cancer. 2021 08; 153:223-233.
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
-
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
-
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.